P154 Twenty-four month follow-up of the effect of zoledronic acid (ZA) on aromatase inhibitor associated bone loss (AIBL) in postmenopausal women (PMW) with early breast cancer (BCa) receiving adjuvant letrozole (LET)

The Breast ◽  
2007 ◽  
Vol 16 ◽  
pp. S57 ◽  
Author(s):  
A. Brufsky ◽  
K. Lund ◽  
S. Papish ◽  
P. Cobb ◽  
P. Eisenberg ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer

The protective effect of zoledronic acid on bone loss in postmenopausal women with early breast cancer treated with sequential tamoxifen and letrozole: 36-month follow-up.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. e11111-e11111 ◽  
Author(s):  
J. Greenberg ◽  
S. M. Stemmer ◽  
R. Bernstein-Molho ◽  
S. Pelles-Avraham ◽  
I. Stephansky ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Protective Effect ◽  
Postmenopausal Women ◽  
Early Breast Cancer

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole

Cancer ◽  
2008 ◽  
Vol 112 (5) ◽  
pp. 1001-1010 ◽  
Author(s):  
Nigel J. Bundred ◽  
Ian D. Campbell ◽  
Neville Davidson ◽  
Richard H. DeBoer ◽  
Holger Eidtmann ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Zoledronic Acid ◽  
Bone Loss ◽  
Aromatase Inhibitor ◽  
Postmenopausal Women ◽  
Early Breast Cancer ◽  
Effective Inhibition
Sign in / Sign up

Export Citation Format

Share Document